Bof F, Maddalena G, Van K Morris II, Parseghian C, Higbie V, Eluri M, Morelli MP, YC Shen JP, Huey RW, Willis J, Kee BK, Haldar S, Martinez SA, Lonardi S, Bergamo F, Singh Raghav KP, Dasari A, Overman MJ, Kopetz S , Bent AH
In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist 1 The trial met both weight loss primary endpoints and its key secondary endpoint evaluating waist circumference, a predictor of cardiometabolic risk, together demonstrating survodutide's potential to broadly improve metabolic health 1 In addition to these positive results, Boehringer is advancing its broad metabolic health R&D program, exploring multiple pharmaceutical approaches to weight management including oral treatments Ingelheim, Germany
J.PountneyD
At TrimRx, we do more than just provide access to a prescription
It is well known that nervous system dysfunction can lead to depression
Similar studies conducted earlier have also shown higher counts of total cells [68, 69] and lower apoptotic cells [69] in bovine embryos cultured in 0.3 mg/mL L-carnitine
